ClinicalTrials.gg
Not yet recruitingNCT07563023Updated May 1, 2026

Exploratory Study on the Treatment of EB Virus Positive HIV Associated Lymphoma With EBV mRNA Vaccine

An Early Phase 1 interventional study of EBV mRNA vaccine in HIV Associated Lymphoma, sponsored by West China Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by West China Hospital · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

HIV related lymphoma is characterized by high pathological malignancy, late disease course, poor bone marrow reserves, immune deficiency, and high risk of infection. It is still one of the main causes of death in AIDS patients. EB virus is believed to be involved in the pathogenesis of approximately half of HIV related NHL and almost all HIV related HL; EBV can be found in almost all patients with primary HIV associated central nervous cell lymphoma (PCNSL). With the widespread application of antiretroviral (ART), the incidence rate of NHL has decreased by about 50% due to the reduction of PCNSL and DLBCL immunoblastic subtypes. However, the burden of HIV related BL and HL has increased.

The immune efficacy targeting EBV may provide a new treatment option for EBV positive HIV associated lymphoma. The EBV mRNA vaccine in this study has shown potential anti-tumor efficacy in lymphoma. Considering the close relationship between EBV and the occurrence and development of HIV associated lymphoma, and the lack of standard first-line and second-line treatment options for this population, we plan to continue exploring the application of this product in more types of lymphoma based on previous research.

02

Conditions studied

  • HIV Associated Lymphoma
03

In context

Lead sponsor

West China Hospital is the lead sponsor of 503 studies on the registry; 247 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Male or female patients aged ≥ 18 years during screening.
  • 2. Histological or cytological diagnosis of associated lymphoma, including but not limited to diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Hodgkin lymphoma (HL), etc.:

    1. Initial treatment population: patients who have not received systematic anti-tumor treatment;
    2. Relapse resistant population: patients who have received at least treatment in the past and have experienced treatment failure or intolerance; Relapse is defined as the appearance of new lesions at the primary site or other locations after achieving complete remission (CR); Difficult to treat is defined as any of the following situations: (1) failure to achieve PR after ≥ 2 treatment cycles; (2) failure to achieve CR after ≥ 4 treatment cycles; (3) failure to achieve complete remission after hematopoietic stem cell transplantation; (4) If the best therapeutic effect or end cause is PD, the number of cycles is not required (the same definition applies to lymphoma in the following text).
  • 3. Positive for EB virus infection (tissue EBER ISH/FISH testing).
  • 4. Complete at least 2 cycles of systemic chemotherapy without achieving CR (the initial treatment population must complete the entire chemotherapy course of the first-line treatment plan, unless intolerant).
  • 5. physical condition score: 0-2 points.
  • 6. Expected survival period ≥ 3 months.
  • 7. The main organ functions well, and the relevant examination indicators meet the following requirements:
  • 8. The subject has no pregnancy plan during the treatment period and agrees to voluntarily take effective measures during the trial period and within 4 months of stopping treatment, and the pregnancy of women of childbearing age is negative.
  • 9. Able to understand and voluntarily sign a written form before the experiment.
  • 10. Able to communicate well with researchers and willing to follow the protocol to complete the experiment.

Exclusion criteria

Exclusion Criteria:

  • 1. The patient has a history of other tumors, except for the cured skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ, gastrointestinal intramucosal carcinoma and other malignant tumors that the researchers think can be included.
  • 2. Known to have aggressive NK cell leukemia or concomitant hemophagocytic syndrome.
  • 3. Known to have uncontrolled cardiac clinical symptoms or diseases, such as (NYHA) grade II or above heart failure, unstable angina, myocardial infarction within 6 months, and requiring treatment or intervention in patients with supraventricular or ventricular arrhythmias.
  • 4. Any active disease or autoimmune disease history, including but not limited to immune related neurological disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain Barre syndrome, myasthenia gravis, systemic lupus erythematosus (SLE), connective tissue disease, scleroderma, inflammatory bowel disease, including Crohn's disease and ulcerative colitis, autoimmune hepatitis, toxic epidermal necrolysis (TEN) or Stevens Johnson syndrome (except for type I diabetes mellitus using a stable dose of insulin).
  • 5. If there are any uncontrollable clinical diseases (such as respiratory, circulatory, digestive, nervous, hematological, urogenital, endocrine system diseases) or mental illnesses (such as depression, schizophrenia) or other major diseases that, according to the researcher's assessment, may hinder the provision of , interfere with the interpretation of the trial results, pose risks to the subjects participating in this trial, or otherwise affect the achievement of the trial objectives.
  • 6. Patients with a known history of interstitial pneumonia or highly suspected of having interstitial pneumonia; Patients with lung abnormalities that may interfere with the detection or management of suspected drug-related pulmonary toxicity during the trial period.
  • 7. Allergic to the experimental drug (including any ). Previous history of severe allergies to any medication, food, or vaccine, such as anaphylactic shock, allergic laryngeal edema, allergic dyspnea, allergic purpura, thrombocytopenic purpura, local allergic necrosis reaction (Arthus reaction), etc.
  • 8. Patients who have had less than 4 weeks or 5 half lives (whichever is shorter) since their last anti-tumor treatment, or whose anti-tumor treatment-related adverse reactions (excluding hair loss) have not recovered to ≤ 1 or baseline standards after previous anti-tumor treatments.
  • 9. Subjects who receive systemic therapy with (>10 mg/day of prednisone or equivalent doses of other corticosteroids) or other agents within 14 days or 5 half lives (whichever is shorter) prior to the first administration. In the absence of active autoimmune diseases, inhalation or topical use of steroids and adrenal hormone replacement with a dose ≤ 10 mg/day of prednisone therapeutic dose is allowed.
  • 10. Within 3 months prior to the first administration, have received mRNA vaccines or similar nanoparticles such as LNP for drug delivery.
  • 11. Previously received organ transplantation or hematopoietic stem cell transplantation.
  • 12. Blood donation or significant blood loss (>450 mL) within the first 3 months of screening.
  • 13. Those who have undergone major surgery within the 4 weeks prior to screening (excluding minor surgeries such as catheter placement or surgery as required by the protocol), or whose impact of surgery or trauma has been eliminated for less than 14 days prior to enrollment.
  • 14. Have a history of drug abuse or known medical, psychological, or social conditions, such as a history of alcohol or drug abuse.
  • 15. Known B virus, virus, and syphilis infection, or hepatitis B B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C virus antibody (HCVAb), and treponema pallidum (TP) antibody were positive when screening: HBsAg (+) or HBcAb (+), and HBV DNA copy number ≥ 2000 IU/mL (or the lower limit of positive detection value in the research center); HCVAb positive and HCV RNA ≥ of the research center.
  • 16. The patient has a history of active pulmonary tuberculosis (TB) or active TB; Or severe acute or chronic infections that require systemic treatment.
  • 17. Pregnant or lactating women.
  • 18. The researchers believe that there are any other factors that are not suitable for the subjects to enter this trial.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    EBV mRNA vaccine, DL 1

    Biological: EBV mRNA vaccine

  • Experimental
    EBV mRNA vaccine, DL 2

    Biological: EBV mRNA vaccine

Interventions

  • BiologicalEBV mRNA vaccine

    EBV mRNA vaccine

06

What researchers measure

Primary outcomes

  1. Safety: Dose limiting toxicity (DLT) and its incidence rate

    Time frame: Within 14 days after the first administration

  2. Safety: Extended Recommended Dose (RDE)

    Time frame: Through study completion, an average of 2 years

Secondary outcomes

  1. Objective response rate (ORR)

    Time frame: Through study completion, an average of 2 years

  2. Disease control rate (DCR)

    Time frame: Through study completion, an average of 2 years

  3. Duration of Relief (DoR)

    Time frame: From the date of the first PR/CR to the date of the first confirmation of progress or death for any reason, whichever came first, assessed up to 2 years

  4. progression free survival (PFS)

    Time frame: From the date of initial treatment until the first confirmation of progression or death for any reason, whichever came first, assessed up to 2 years

  5. overall survival (OS)

    Time frame: From the date of initial treatment until the death for any reason, assessed up to 2 years

  6. Immunogenicity: antigen-specific T cell expression levels

    Time frame: Through study completion, an average of 2 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for Dec 2027, 19 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2026
First posted
May 1, 2026
StartEst.
May 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07563023
Responsible party
Xingchen Peng (Professor, West China Hospital) — Principal investigator
First posted
May 1, 2026
Start date
May 1, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
May 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion